MA (EU) number 
(Invented) 
name 
Strength 
Pharmaceutical 
Form 
Route of 
Administration 
Immediate 
Packaging 
Content 
(concentration) 
Pack size 
EU/1/21/1618/001  Nuvaxovid 
EU/1/21/1618/002 
Nuvaxovid 
EU/1/21/1618/003 
Nuvaxovid 
EU/1/21/1618/004 
Nuvaxovid 
EU/1/21/1618/006  Nuvaxovid 
XBB.1.5 
EU/1/21/1618/008  Nuvaxovid 
XBB.1.5 
--¹ 
--¹ 
--¹ 
--¹ 
--2 
--2 
Dispersion for 
injection 
Dispersion for 
injection 
Dispersion for 
injection 
Dispersion for 
injection 
Dispersion for 
injection 
Dispersion for 
injection 
Intramuscular use  Vial (glass) 
5 mL (10 doses) 
Intramuscular use 
Vial (glass) 
2.5 mL (5 doses) 
Intramuscular use 
Vial (glass) 
5 mL (10 doses) 
Intramuscular use 
Vial (glass) 
2.5 mL (5 doses) 
Intramuscular use  Vial (glass) 
2.5 mL (5 doses) 
Intramuscular use  Vial (glass) 
2.5 mL (5 doses) 
10 multidose vials 
(100 doses)  
10 multidose vials 
(50 doses)  
2 multidose vials 
(20 doses) 
2 multidose vials 
(10 doses)  
10 multidose vials 
(50 doses)  
2 multidose vials 
(10 doses) 
--¹ 
One dose (0.5 mL) contains 5 micrograms of the of SARS-CoV-2 spike protein* and is adjuvanted with Matrix-M. 
Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 micrograms) and Fraction-C (7.5 micrograms) of Quillaja saponaria Molina extract. 
* produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera 
frugiperda species.  
--2 
One dose (0.5 mL) contains 5 micrograms of the of SARS-CoV-2 (Omicron XBB.1.5) spike protein* and is adjuvanted with Matrix-M. 
Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 micrograms) and Fraction-C (7.5 micrograms) of Quillaja saponaria Molina extract. 
* produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera 
frugiperda species.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
